Dr. Tagawa explains the rationale for EVOLUTION, a phase II analysis of Lu-PSMA-617 with ipilimumab and nivolumab in mCRPC.
CRPC
Advertisement
Latest News
Dr. Tagawa contextualizes a post hoc analysis on clonal hematopoiesis in those who received 177Lu-PSMA-617 or cabazitaxel.
Dr. Tagawa showcases the ProstACT Global trial, a phase III study of 177Lu-rosptamab in patients with mCRPC.
Dr. Tagawa breaks down the VIOLET study, a single-arm phase I/II first-in-human results of terbium-161Tb-PSMA-I&T.
Dr. Ozay discusses her study that compared the efficacy of cabazitaxel with lutetium Lu-177 in patients with mCRPC.
Louise Emmett, MD, discusses the ENZA-p trial which studied enzalutamide versus enzalutamide plus [177Lu] Lu-PSMA-617.
Researchers studied clonal hematopoiesis mutations in patients treated with 177Lu-PSMA-617 or cabazitaxel for prostate cancer
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Researchers investigated the efficacy of platinum plus 5-FU in the treatment of patients with high-risk penile cancer.
Dr. Attard explores how the study's results compare with prior data in the metastatic castration-resistant setting.
Avelumab plus sacituzumab govitecan may improve PFS in patients with advanced bladder cancer.
At 12 months, the OS rate for patients who received treatment with ipilimumab plus nivolumab was superior to SOC.
The Two Onc Docs review QOL related to doublet ADT with darolutamide, niraparib with abiraterone for mCSPC, and more.
The Two Onc Docs review the 5-year follow-up data on adjuvant pembro and a final analysis on ipi/nivo for metastatic disease.
Advertisement
Advertisement
Trending
Researchers investigated the efficacy of platinum plus 5-FU in the treatment of patients with high-risk penile cancer.
Dr. Attard explores how the study's results compare with prior data in the metastatic castration-resistant setting.
Almost 30% of patients will experience recurrence while undergoing EBRT that will require ADT and salvage therapies.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.